POY_1170x120_8-12-19

Dr. Reddy’s Laboratories

Upsher-Smith acquires two products from Dr. Reddy’s

Upsher-Smith acquires two products from Dr. Reddy’s

MAPLE GROVE, Minn. – Upsher-Smith recently announced that it has completed the acquisition of Tosymra (sumatriptan) Nasal Spray, 10 mg, and Zembrace SymTouch (sumatriptan) Injection 3 mg from Dr. Reddy’s Laboratories. The products were previously commercialized through Dr. Reddy’s wholly owned subsidiary, Promius Pharma. Both medications are indicated for the acute treatment of migraine with

Dr. Reddy’s gets FDA approval for Tosymra

Dr. Reddy’s gets FDA approval for Tosymra

PRINCETON, N.J. — Dr. Reddy’s Laboratories and its subsidiary, Promius Pharma. today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute treatment of migraine with or without aura in adults. Tosymra is the latest product to join the Promius Pharma acute migraine treatment

Dr. Reddy’s launches sevelamer carbonate for oral suspension in U.S.

Dr. Reddy’s launches sevelamer carbonate for oral suspension in U.S.

PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of sevelamer carbonate for oral suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the U.S. Food and Drug Administration. The Renvela brand and generic had U.S. sales of approximately $101 million MAT

Dr. Reddy’s rolls out aspirin and extended-release dipyridamole capsules

Dr. Reddy’s rolls out aspirin and extended-release dipyridamole capsules

PRINCETON, N.J. — Dr. Reddy’s Laboratories Ltd. recently announced the launch of aspirin and extended-release dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules in the United States market from the U.S. Food and Drug Administration. The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for

Dr. Reddy’s releases generic version of Strattera

Dr. Reddy’s releases generic version of Strattera

HYDERABAD, India and PRINCETON, N.J . — Dr. Reddy’s Laboratories announced the roll out of its atomoxetine capsules. The product is for the treatment of attention-deficit/hyperactivity disorder, is a generic version of Eli Lilly’s Strattera. Dr. Reddy’s atomoxetine capsules are available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100

Dr. Reddy’s receives approval for aspirin and extended-release dipyridamole capsules

Dr. Reddy’s receives approval for aspirin and extended-release dipyridamole capsules

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories  announced receipt of approval for aspirin and extended-release dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration. The company is working towards launching the product. The Aggrenox brand and

Dr. Reddy’s rolls out generic of Plaquenil

Dr. Reddy’s rolls out generic of Plaquenil

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of hydroxychloroquine sulfate tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil (hydroxychloroquine sulfate) tablets, in the U.S. market, approved by the U.S. Food and Drug Administration. The Plaquenil brand and generic had U.S. sales of approximately $215 million MAT for

Dr. Reddy’s gets FDA approval, launches generic version of Suboxone

Dr. Reddy’s gets FDA approval, launches generic version of Suboxone

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and

Dr. Reddy’s releases store-brand version of Xyzal Allergy 24HR

Dr. Reddy’s releases store-brand version of Xyzal Allergy 24HR

PRINCETON, N.J. — Dr. Reddy’s Laboratories has launched levocetirizine dihydrochloride tablets 5 mg, an over-the-counter allergy medication, in the U.S. market. Dr. Reddy’s said its levocetirizine dihydrochloride tablets are a generic version of Xyzal Allergy 24HR Tablets from Chattem-Sanofi. The 5-mg Dr. Reddy’s product comes in various consumer-oriented package sizes. “This first-to-market launch for the

Dr. Reddy’s releases Wellbutrin SR generic

Dr. Reddy’s releases Wellbutrin SR generic

HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. has launched bupropion HCl extended-release tablets, an antidepressant medication. Dr. Reddy’s said its product, a generic version of Wellbutrin SR sustained-release tablets from GlaxoSmithKline, comes in strengths of  100 mg, 150 mg and 200 mg in 60-, 100- and 500-count bottles. An antidepressant of the aminoketone drug class,

Promius Pharma debuts new corporate identity

Promius Pharma debuts new corporate identity

PRINCETON, N.J. — Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, has unveiled its new visual identity and corporate brand: The Power of Humans Being. The initiative is designed to express the core belief at Promius Pharma that “every patient is a person first” and its mission to “help patients get back to what

Dr. Reddy’s makes foray into OTC health arena

Dr. Reddy’s makes foray into OTC health arena

HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. has acquired six over-the-counter health product brands from Ducere Pharma LLC. Financial terms of the agreement weren’t disclosed. India-based Dr. Reddy’s, which has its U.S. office in Princeton, N.J., said the deal brings the company into the consumer health care arena. The brands being acquired from New Hope,

CutisPharma, Dr. Reddy’s announce API agreements

CutisPharma, Dr. Reddy’s announce API agreements

WILMINGTON, Mass. — CutisPharma has entered into active pharmaceutical ingredient (API) supply and joint development pacts with Dr. Reddy’s Laboratories Ltd. CutisPharma, which focuses on products for the prescription compounding market,  said Tuesday that it aims to advance several programs in its research and development portfolio — including RM-02, RM-03 and RM-06 — toward Food

Promius Pharma to release Sernivo Spray

Promius Pharma to release Sernivo Spray

PRINCETON, N.J. — Promius Pharma LLC has received Food and Drug Administration approval for Sernivo Spray 0.05%, a psoriasis medication. A prescription topical steroid, Sernivo Spray (betamethasone dipropionate 0.05%) is indicated for the treatment of mild to moderate plaque psoriasis in adult patients, according to Promius, the U.S. subsidiary of India-based Dr. Reddy’s Laboratories. “The